The most recent FDA-approved ASO drug is casimersen, which is used for the treatment of Duchenne muscular dystrophy (DMD) and works by inducing the exon 45 skipping of dystrophin so functional dystrophin can be translated [239,240,241]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.